Cost-effectiveness analysis of pertuzumab with trastuzumab in patients with metastatic breast cancer

Addition of pertuzumab to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer is associated with improved overall survival. The cost-effectiveness of addition to pertuzumab is not yet clear. A population-based retrospective study in Ontario found that pertuzumab resulted in 0.61 life-years gained and 0.44 QALYs gained at an incremental cost of Canadian $ 192,139 with an ICER of $ 316,203 per life-year gained and $ 436,679 per QALY gained. The authors conclude that addition of pertuzumab to trastuzumab and chemotherapy for metastatic breast cancer would not be considered cost-effective, even after 100% price reduction, under conventional thresholds.